Press Releases for OSIP

Press Releases
OSI Pharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
OSI Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference on Wednesday, August 5, 2009
Hercules Technology Growth Capital Announces Successful Fund Raising Activities From Select Life Sciences Portfolio Companies Despite Challenging Economy
StockPreacher.com Issues Trading Outlook for Onyx Pharmaceuticals Inc. (ONXX)
OSI Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
OSI Pharmaceuticals and AVEO Pharmaceuticals Expand Oncology Discovery and Translational Research Collaboration
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
OSI Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 22, 2009
OSI Pharmaceuticals Announces Consolidation of U.S. Operations
OSI Pharmaceuticals Announces Acceptance of Tarceva Supplemental New Drug Application for Review by the U.S. Food and Drug Administration
MaybachFinancial.Com Posts Free Analyst Report on WY, XTO, BIIB and OSIP
OSI Pharmaceuticals to Present at the Goldman Sachs 30th Annual Global Healthcare Conference on Tuesday, June 9, 2009
Data from the Phase III ATLAS Study Show Tarceva in Combination with Avastin as First-Line Maintenance Therapy Improved Progression-Free Survival in Advanced Lung Cancer
Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
OSI Pharmaceuticals to Provide a Summary of Data Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
OSI Pharmaceuticals Provides Update on OSI-906 Data Being Presented on May 30th at the Upcoming Annual Meeting of the American Society of Clinical Oncology (ASCO)
CORRECTING AND REPLACING Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
Data from the Phase III SATURN Study Show Tarceva Improved Progression-Free Survival When Used as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
OSI Pharmaceuticals to Present at the Deutsche Bank 34th Annual Health Care Conference on Tuesday, May 19, 2009
OSI Pharmaceuticals Provides Update on Diabetes and Obesity Clinical Programs
OSI Pharmaceuticals to Present at the Canaccord Adams 2009 Diabetes and Obesity Conference on Tuesday, May 12, 2009
OSI Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
OSI Pharmaceuticals to Announce First Quarter 2009 Financial Results on April 29, 2009
AnalystChoice.Com Free Investment Opinion on PPDI, MEDX, CVTX and OSIP
SAS Launches Physician Targeting Solution
VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
OSI Pharmaceuticals Announces Conversion Period for Convertible Notes - Apr 3 2009 8:07AM
VIA Pharmaceuticals Complies With NASDAQ Rules - Mar 27 2009 8:55PM
VIA Pharmaceuticals Complies With NASDAQ Rules - Mar 27 2009 4:56PM
OSI Pharmaceuticals Files Patent Infringement Lawsuits Against Teva Pharmaceuticals USA and Mylan Pharmaceuticals
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Over 80 Life Science Industry Exhibitors at the NYBA Annual Meeting
OSI Pharmaceuticals to Present at the Cowen and Company 29th Annual Healthcare Conference on Monday, March 16, 2009
Standard & Poor's Announces Changes to U.S. Indices - 05-03-09
OSI Pharmaceuticals Response to Initial Non-Final Office Action by U.S. Patent and Trademark Office
OSI Pharmaceuticals, Inc. Announces Year End 2008 Financial Results
OSI Pharmaceuticals Announces Notification of ANDA Filing for Tarceva
OSI Pharmaceuticals to Announce Fourth Quarter and Year-End 2008 Financial Results on February 19, 2009
OSI Pharmaceuticals to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13, 2009
Zacks Analyst Blog Highlights: Royal Dutch Shell, Plc, Amylin Pharmaceuticals Inc., Eli Lilly, OSI Pharmaceuticals, Inc., And NCI Building Systems Inc.
OSI Pharmaceuticals Announces the Appointment of Mr. Pierre Legault as Executive Vice President and Chief Financial Officer
Tarceva® (erlotinib) Endorsed by the U.K.’s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 4th
OSI Pharmaceuticals to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
OSI Pharmaceuticals to Present at the Lazard Annual Healthcare Conference on Tuesday, November 18, 2008
Phase III Study (SATURN) Showed Tarceva Improved Progression-Free Survival as a First-Line Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
OSI Pharmaceuticals Announces Third Quarter 2008 Financial Results
OSI Pharmaceuticals to Announce Third Quarter Financial Results on October 22, 2008
Zacks Analyst Blog Highlights: The Potash Corporation of Saskatchewan, Inc., Freddie Mac, Fannie Mae, OSI Pharmaceuticals, Inc. And Stoneridge, Inc.
Genentech and OSI Pharmaceuticals Announce Topline Results from Phase III Study Evaluating the Combination of Avastin and Tarceva as Second-Line Treatment for Advanced Non-Small Cell Lung Cancer
OSI Pharmaceuticals Announces Conversion Period for Convertible Notes - Oct 1 2008 1:42PM
OSI Pharmaceuticals to Present at the UBS Global Life Sciences Conference on Monday, September 22, 2008
Semi-annual Changes to the NASDAQ Q-50 Index - Sep 15 2008 7:12AM
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Diabetes Candidate, PSN821
OSI Pharmaceuticals Announces Second Quarter 2008 Financial Results
OSI Pharmaceuticals Begins Clinical Development Program for OSI-027 in Patients with Advanced Solid Tumors or Lymphoma
OSI Pharmaceuticals to Announce Second Quarter Financial Results on July 23, 2008
OSI Pharmaceuticals Announces Conversion Period for Convertible Notes - Jul 3 2008 8:16AM
OSI Pharmaceuticals Initiates Clinical Development Program for Anti-Obesity Candidate, PSN602
OSI Pharmaceuticals Presents Diabetes/Obesity Preclinical Compounds, PSN821 and PSN602, at Annual Meeting of the American Diabetes Association
OSI Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference on Thursday, June 12, 2008
New Analyst Reports for OSI PHARMACEUTICALS INC, CITRIX SYSTEMS INC, AMYLIN PHARMACEUTICALS INC, and IMCLONE SYSTEMS INCORPORATED
OSI Pharmaceuticals to Provide a Summary of Data Presented at the 2008 American Society of Clinical Oncology Meeting
New York Biotechnology Association Executive Director and Biotechnology Industry Leaders to Ring The NASDAQ Stock Market Opening Bell
OSI Pharmaceuticals to Present at the Citi Global Healthcare Conference on Thursday, May 22, 2008 - May 27 2008 12:53AM
OSI Pharmaceuticals Announces First Quarter 2008 Financial Results - Jun 2 2008 1:04AM
OSI Pharmaceuticals to Present at the Bank of America Healthcare Conference on Tuesday, May 13, 2008 - Jun 2 2008 1:04AM
OSI Pharmaceuticals to Announce First Quarter Financial Results on May 6, 2008
OSI Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 1, 2008
OSI Pharmaceuticals Summarizes Data Presented at the Annual Meeting of the American Association for Cancer Research
OSI Pharmaceuticals Announces Conversion Period for Convertible Notes - Jun 2 2008 1:03AM